- Certara recently highlighted that its Simcyp physiologically-based pharmacokinetic modeling was accepted by the U.S. FDA in place of multiple clinical pharmacology studies to support the new drug application for asciminib (Scemblix®), an allosteric BCR::ABL1 inhibitor for Chronic Myeloid Leukemia.
- This decade-long modeling effort, which replaced at least ten dedicated clinical studies and informed dosing and drug-interaction decisions, underscores how biosimulation can cut development costs and time while strengthening the evidence package for regulatory approvals.
- With FDA acceptance of Simcyp modeling replacing multiple asciminib studies now in focus, we’ll explore how this milestone reshapes Certara’s investment narrative.
Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
Certara Investment Narrative Recap
To own Certara, you have to believe biosimulation will keep gaining regulatory traction and become embedded in drug development workflows. The asciminib decision, where Simcyp modeling replaced at least ten clinical pharmacology studies, reinforces that core thesis but does not change the near term pressure point: translating scientific wins into faster revenue growth against a backdrop of cautious pharma spending and modest 2026 guidance, while the biggest risk remains that adoption and ROI on heavy R&D and AI investment lag expectations.
Against this backdrop, the recent 2026 revenue guidance of 0% to 4% growth sits in sharp contrast to the scientific milestone. It highlights the tension between strong regulatory validation of tools like Simcyp and the current commercial reality implied by flat to low single digit growth, reminding investors that even high profile FDA use cases may take time to filter through to bookings, margins, and the broader software mix that many see as Certara’s key long term earnings engine.
Yet behind the scientific win, investors should be aware that the real risk may be slower than expected customer adoption and ROI on Certara’s growing R&D spend...
Read the full narrative on Certara (it's free!)
Certara’s narrative projects $519.5 million revenue and $7.4 million earnings by 2028. This requires 8.6% yearly revenue growth and a $0.6 million earnings decrease from $8.0 million today.
Uncover how Certara's forecasts yield a $12.38 fair value, a 75% upside to its current price.
Exploring Other Perspectives
Before this FDA milestone, the most optimistic analysts were assuming revenue could reach about US$535.4 million and earnings US$58.6 million by 2028, which is a much more optimistic path than consensus. If you are weighing that view against the risk that organic growth stays stuck in the low single digits, this asciminib decision could eventually shift expectations, but it also underscores how far opinions can differ on where Certara’s growth story goes next.
Explore 3 other fair value estimates on Certara - why the stock might be worth over 2x more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Certara research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Certara research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Certara's overall financial health at a glance.
Interested In Other Possibilities?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com